Lassen Therapeutics

19 articles about Lassen Therapeutics

• Lassen Therapeutics Announces Closing of Oversubscribed $85 Million Series B Financing and Announces First Patient Dosed in the Phase 1 Trial Evaluating LASN01 in Thyroid Eye Disease

  12/19/2023

  Lassen Therapeutics today announced the closing of an oversubscribed Series B financing which raised $85 million.

• Lassen Therapeutics Presents Preclinical Data on LASN01, an Anti-IL-11 Receptor Antibody in Development for Treatment of Thyroid Eye Disease at the American Thyroid Association 2023 Annual Meeting

  10/2/2023

  Lassen Therapeutics presented new preclinical data on LASN01, for treatment of TED, at the American Thyroid Association (ATA) Annual Meeting held in Washington DC, September 27 through October 1, 2023.

• Lassen Therapeutics Presents New Data on LASN01 for the Treatment of Idiopathic Pulmonary Fibrosis and Thyroid Eye Disease at the European Respiratory Society (ERS) and European Thyroid Association (ETA) Annual Meetings

  9/11/2023

  Lassen Therapeutics today announced new clinical and preclinical data generated with LASN01 at the 2023 European Respiratory Society (ERS) International Congress and the 45th Annual Meeting of the European Thyroid Association (ETA).

• Lassen Therapeutics Presents Phase I Data on LASN01, an IL-11 Receptor-Blocking Antibody for Treatment of Pulmonary Fibrosis, at the American Thoracic Society 2023 Annual Meeting

  5/24/2023

  Lassen Therapeutics presented new preclinical and Phase I data of LASN01 for treatment of pulmonary fibrosis, at today’s American Thoracic Society (ATS) Annual Meeting being held in Washington DC.

• Lassen Therapeutics Announces Oral Presentation of Phase I Data of LASN01, an IL-11 Receptor-Blocking Antibody for Treatment of Pulmonary Fibrosis, at the American Thoracic Society 2023 Annual Meeting

  5/9/2023

  Lassen Therapeutics will present new preclinical and Phase I data of LASN01, a potential first-in-class IL-11 receptor (IL-11R) blocking antibody in development for treatment of pulmonary fibrosis, at the American Thoracic Society (ATS) Annual Meeting being held in Washington DC, May 19-24, 2023.

• Lassen Therapeutics Presents Data Demonstrating Anti-IL18 Binding Protein Antibody Efficacy and Enhancement of Anti-Tumor Immunity at AACR Annual Meeting

  4/17/2023

  Lassen Therapeutics, a clinical-stage biotech company developing breakthrough antibody therapeutics as potential treatments for immuno-fibrotic diseases and cancer, will present new preclinical data demonstrating activity of its anti-interleukin-18 binding protein (IL-18BP) antibody and efficacy in combination with anti-PD-1 at the American Association for Cancer Research (AACR) Annual Meeting 2023.

• Lassen Therapeutics Commences Dosing in Phase 1 Clinical Study of LASN01, a First-in-Class Interleukin-11 Receptor-Blocking Antibody

  9/28/2022

  Lassen Therapeutics today announced the initiation of dosing in a Phase 1 study of LASN01, a novel interleukin-11 (IL-11) receptor-blocking antibody.

• Lassen Therapeutics Presents New Preclinical Data on IL-11 Receptor-blocking as a Novel Therapeutic Approach for Skin Fibrosis at Keystone Symposia Conference

  6/15/2022

  Lassen Therapeutics presented new preclinical data on LASN01, a monoclonal antibody targeting IL-11 receptor, in preclinical models of skin fibrosis at the Keystone Symposia Conference on Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies being held in Keystone, Colorado.

• Lassen Therapeutics Announces Presentation at Keystone Symposia Conference on IL-11 Receptor-blocking as a Novel Therapeutic Approach for Lung Fibrosis

  5/26/2022

  Lassen Therapeutics, a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today announced plans to present a poster on IL-11 receptor-blocking as a novel therapeutic approach for lung fibrosis at the upcoming Keystone Symposia Conference.

• Lassen Therapeutics Presents Data Demonstrating Preclinical Anti-fibrotic Effect of LASN01, a Novel IL-11 Receptor-Blocking Antibody, at the American Thoracic Society 2022 Annual Meeting

  5/17/2022

  Lassen Therapeutics , a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, is presenting new preclinical data on LASN01.

• Lassen Therapeutics Announces Presentations on Novel IL-11 Receptor-Blocking Antibody at the American Thoracic Society 2022 Annual Meeting

  5/3/2022

  Lassen Therapeutics today announced upcoming presentations of new data on its novel IL-11 receptor-blocking antibody at the American Thoracic Society (ATS) Annual Meeting being held in San Francisco, May 13-18, 2022.

• Lassen Therapeutics Appoints Puneet S. Arora M.D. as Chief Medical Officer

  11/18/2021

  Lassen Therapeutics today announced the appointment of Puneet S. Arora, M.D. as Chief Medical Officer.

• Lassen Therapeutics Announces the Appointment of a Highly Experienced Biotech Executive to its Board of Directors and the Expansion of its Scientific and Clinical Advisory Board with Leading Experts in Pulmonary Fibrosis and Clinical Development

  10/7/2021

  Lassen Therapeutics today announced the appointment of a highly experienced industry executive and recognized clinical thought leaders to its team. Lisa Olson, Ph.D., joins the Board of Directors and Bill Bradford, M.D., Ph.D., Paul W. Noble, M.D., and Toby Maher, M.B.B.S., M.Sc., Ph.D.

• Lassen Therapeutics to Present at the 5th Annual Idiopathic Pulmonary Fibrosis (IPF) Summit

  8/26/2021

  Lassen Therapeutics today announced that Jamie Swaney, Ph.D., Vice President of Fibrosis & Translational Biology, is presenting at the 5th Annual IPF Summit on Friday, August 27, 2021.

• Lassen Therapeutics Announces Collaboration with Cedars Sinai Medical Center to Study the Role of IL-11 Signaling and Inhibition in Preclinical Models of Lung Fibrosis

  3/25/2021

  Goal is to generate proof of principle and mechanistic understanding of the efficacy of antibodies targeting IL-11 receptor in idiopathic pulmonary fibrosis

• Lassen Therapeutics Announces Collaboration with the Olivia Newton-John Cancer Research Institute to Study the Role of IL-11 Signaling and Inhibition in Preclinical Models of Breast Cancer

  2/9/2021

  Lassen Therapeutics , a biotechnology company developing antibodies as potential treatments for fibrosis and oncology, today announced a collaboration with the Olivia Newton-John Cancer Research Institute (ONJCRI) in Melbourne, Australia.

• Lassen Therapeutics Announces Formation of Scientific Advisory Board

  12/16/2020

  Lassen Therapeutics , a biotech company developing innovative antibodies as potential treatments for fibrosis, rare diseases and oncology, today announced the formation of its scientific advisory board. Lassen’s lead molecule, LASN01, is a best-in-class monoclonal antibody targeting the interleukin-11 (IL-11) receptor. The newly formed SAB will work closely with Lassen’s leadership team to further advance research and develop

• Lassen Therapeutics Launches to Discover and Develop Novel Antibody Therapeutics Including Lead Program Targeting IL-11 to Treat Fibrosis and Oncology

  6/17/2020

  Lassen Therapeutics announced it has emerged from stealth and secured $31 million in Series A financing to develop antibodies as potential treatments for fibrosis, rare diseases and oncology.

• 

  Lassen Therapeutics Raises $31 Million to Pursue IL-11 Antibody for Cancer and Fibrosis

  6/17/2020

  Lassen Therapeutics, based in San Diego, came out of stealth mode with a $31 million Series A financing round. The round was led by Frazier Healthcare Partners with participation from Alta Partners and Longwood Fund.